As of 2025-07-11, the Intrinsic Value of VIVA Biotech Holdings (1873.HK) is 1.02 HKD. This 1873.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.46 HKD, the upside of VIVA Biotech Holdings is -30.40%.
The range of the Intrinsic Value is 0.47 - 2.63 HKD
Based on its market price of 1.46 HKD and our intrinsic valuation, VIVA Biotech Holdings (1873.HK) is overvalued by 30.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.47 - 2.63 | 1.02 | -30.4% |
| DCF (Growth 10y) | 9.46 - 33.64 | 15.55 | 964.9% |
| DCF (EBITDA 5y) | 16.90 - 24.59 | 18.78 | 1186.6% |
| DCF (EBITDA 10y) | 34.20 - 59.17 | 41.69 | 2755.6% |
| Fair Value | 0.43 - 0.43 | 0.43 | -70.56% |
| P/E | 1.29 - 3.79 | 2.03 | 39.2% |
| EV/EBITDA | 3.56 - 5.01 | 4.21 | 188.6% |
| EPV | (0.11) - (0.07) | (0.09) | -106.3% |
| DDM - Stable | 0.46 - 1.55 | 1.00 | -31.2% |
| DDM - Multi | 5.45 - 16.07 | 8.33 | 470.9% |
| Market Cap (mil) | 3,112.40 |
| Beta | 2.18 |
| Outstanding shares (mil) | 2,131.78 |
| Enterprise Value (mil) | 3,487.59 |
| Market risk premium | 5.98% |
| Cost of Equity | 12.10% |
| Cost of Debt | 4.25% |
| WACC | 9.40% |